Phaseline

Companies › Apollo Therapeutics

Apollo Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Cardiovascular, Immunology, Hematology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APL-9796–Phase 2Pulmonary Arterial HypertensionAug 2027
Camoteskimab
Interleukin-18 cross-linking agent
IL18Phase 2Atopic DermatitisOct 2027
APL-4098–Phase 1Acute Myeloid Leukemia RefractoryJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06372717APL-4098Phase 1Acute Myeloid Leukemia RefractoryHematologyJul 2027
NCT06846554APL-9796Phase 2Pulmonary Arterial HypertensionCardiovascularAug 2027
NCT07599813CamoteskimabPhase 2Atopic DermatitisImmunologyOct 2027

Targets

IL18 (1)

Companies with the same targets

Simcha IL-18 GSK

Companies built like this

GCP-Service International West HK inno.N Hemab ApS Viatris Innovation MRM Health

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.